# Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Study · id `cardio:ct-nct05937854` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05937854](<https://clinicaltrials.gov/study/NCT05937854>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05937854

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.

## Technical summary

Registry record NCT05937854. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2029-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT05937854, source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT05937854, source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)
- Primary completion: 2029-03-01 (anticipated) (ClinicalTrials.gov record NCT05937854, source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)
- Completion: 2029-03-01 (anticipated) (ClinicalTrials.gov record NCT05937854, source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05937854, source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05937854-2026-05-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Acronym: BETTER COPD-PH
- Condition: Chronic Obstructive Pulmonary Disease
- Condition: Pulmonary Hypertension
- Condition: Dyspnea
- Intervention (Drug): Tadalafil
- Intervention (Drug): Placebo
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED
- Collaborator: VA Boston Healthcare System
- Collaborator class: FED
- Collaborator: Atlanta VA Medical Center
- Collaborator class: FED
- Collaborator: VA Eastern Colorado Health Care System
- Collaborator class: FED
- Collaborator: VA Nebraska Western Iowa Health Care System
- Collaborator class: FED

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: 1da4d04c2863e0b90b1dd121804f70a5806844fb6b3cdf0624c17c1420240c34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
